诺和诺德（Novo _老虎社区_美港股上老虎

小白的大叔。
08-07

诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润达到555.37亿丹麦克朗。

从诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润

从诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润达到555.37亿丹麦克朗。明星产品中司美格鲁肽上半年销售额达1127.56亿丹

从诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":465099406586104,"tweetId":"465099406586104","gmtCreate":1754574644066,"gmtModify":1754574646195,"author":{"id":3579778221419795,"idStr":"3579778221419795","authorId":3579778221419795,"authorIdStr":"3579778221419795","name":"小白的大叔。","avatar":"https://static.tigerbbs.com/995cc40528b93e7f90a2292a298025aa","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润达到555.37亿丹麦克朗。</p></body></html>","htmlText":"<html><head></head><body><p>诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润达到555.37亿丹麦克朗。</p></body></html>","text":"诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润达到555.37亿丹麦克朗。","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/465099406586104","repostId":2557310605,"repostType":2,"repost":{"id":"2557310605","kind":"live","pubTimestamp":1754550353,"share":"https://www.laohu8.com/m/news/2557310605?lang=&edition=full","pubTime":"2025-08-07 15:05","market":"us","language":"zh","title":"从诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2557310605","media":"智通财经","summary":"从诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润达到555.37亿丹麦克朗。明星产品中司美格鲁肽上半年销售额达1127.56亿丹","content":"<html><body><div>\n<div>\r\n                  从诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润达到555.37亿丹麦克朗。明星产品中司美格鲁肽上半年销售额达1127.56亿丹麦克朗。这之中降糖版司美格鲁肽注射液（英文商品名：Ozempic下同）销售额为645.2亿丹麦克朗减重版司美格鲁肽注射液（Wegovy）销售额为368.88亿丹麦克朗。换算成美元便是司美格鲁肽在今年上半年的销售额达到了175亿美元。这也意味着司美格鲁肽的销售成绩于期内超越了药王帕博利珠单抗也就是俗称的“K药”。                </div>\n</div></body></html>","source":"live_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>从诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n从诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-07 15:05 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>从诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润达到555.37亿丹麦克朗。明星产品中司美格鲁肽上半年销售额达1127.56亿丹麦克朗。这之中降糖版司美格鲁肽注射液（英文商品名：Ozempic下同）销售额为645.2亿丹麦克朗减重版司美格鲁肽注射液（Wegovy）销售额为368.88亿丹麦克朗。换算成美元便是司美格鲁肽在今年...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","NVO":"诺和诺德","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999014559.SGD":"United Income Focus Trust Dis SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","MRK":"默沙东","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BK4599":"减肥药","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H"},"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2557310605","content_text":"从诺和诺德（Novo Nordisk）获悉该公司于今年前6个月实现销售收入1549.44亿丹麦克朗同比增长16%；净利润达到555.37亿丹麦克朗。明星产品中司美格鲁肽上半年销售额达1127.56亿丹麦克朗。这之中降糖版司美格鲁肽注射液（英文商品名：Ozempic下同）销售额为645.2亿丹麦克朗减重版司美格鲁肽注射液（Wegovy）销售额为368.88亿丹麦克朗。换算成美元便是司美格鲁肽在今年上半年的销售额达到了175亿美元。这也意味着司美格鲁肽的销售成绩于期内超越了药王帕博利珠单抗也就是俗称的“K药”。","news_type":1,"symbols_score_info":{"MRK":1,"NVO":1}},"isVote":1,"tweetType":1,"viewCount":455,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["NVO"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":112,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}